Skip to main content

Generics

  • Sandoz launches new dosages of authorized Lotrel generic

    PRINCETON, N.J. — Sandoz has launched higher dosages of its authorized generic version of a hypertension drug, the generics division of Swiss drug maker Novartis said Monday.

    Sandoz announced the launch of amlodipine besylate and benazepril in the 5-mg/40-mg and 10-mg/40-mg strengths. The company already marketed the drug in the 2.5-mg/10-mg, 5-mg/10-mg, 5-mg/20-mg and 10-mg/20-mg strengths.

    The drug is an authorized generic of Lotrel, marketed by Novartis Pharmaceuticals. An authorized generic is a branded drug marketed under its generic name at a reduced price.

  • Glenmark gets FDA OK for three drugs

    MUMBAI, India — The Food and Drug Administration approved three drugs made by Glenmark Generics last month and gave tentative approval to a fourth, the Indian generic drug maker said.

  • FDA rejection of lower-dose Copaxone will likely ward off generic competition

    NEW YORK — One door closes; another door, well, closes. And that appears to be good news for Teva. Recent news that the Food and Drug Administration has rejected the drug maker's application for a new indication for multiple sclerosis drug Copaxone likely will mean the agency will not be so quick to approve a generic version of the drug without requiring a generic company to perform full clinical trials.

  • Marsh implements generic drug pricing offer

    INDIANAPOLIS — Marsh Supermarkets recently implemented a $3.99/$9.99 generic drug pricing offer for 30-day and 90-day prescriptions, respectively.

    The program applies to a designated list of generic drugs at commonly prescribed dosages (higher dosages cost more).

  • Takeda settles patent suits relating to Actos

    DEERFIELD, Ill., and OSAKA, Japan — Takeda and its subsidiary settled the patent suits it brought against generic drug makers that sought to develop their own versions of its diabetes treatment.

  • URAC revises accreditation programs

    WASHINGTON — A healthcare accrediting organization is revising three products in its Pharmacy Quality Management suite of programs.

    URAC said its pharmacy committee approved revisions to its mail service, specialty pharmacy, and workers' compensation and property and casualty for pharmacy benefit management accreditation programs. The products revised include:

    • Mail-service pharmacy, version 2.0;

    • Specialty pharmacy, version 2.0; and

  • Court blocks AstraZeneca's suits over Crestor

    NEW YORK — A judge recently blocked AstraZeneca from attempting to impede the development of generic versions of its popular cholesterol drug, according to published reports.

  • Reform will bolster pharmacy, GAO confirms

    ALEXANDRIA, Va. — A study by the Government Accountability Office confirmed that the health-reform law enacted earlier this year established a more reasonable reimbursement level for pharmacies dispensing generic drugs to patients covered by Medicaid. But pharmacy retailers still face the continued threat of further Medicaid cuts at the state level, the independent pharmacy lobby warned Friday.

X
This ad will auto-close in 10 seconds